Swedbank
VRTX icon

Swedbank’s Vertex Pharmaceuticals VRTX Stock Holding History

Swedbank’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140M Buy
282,444
+10,891
+4% +$4.83M 0.12% 135
2026
Q1 		$121M Buy
271,553
+10,810
+4% +$5.04M 0.13% 137
2025
Q4 		$118M Buy
260,743
+6,647
+3% +$2.87M 0.11% 138
2025
Q3 		$99.5M Sell
254,096
-251
-0.1% -$105K 0.1% 150
2025
Q2 		$113M Sell
254,347
-35,727
-12% -$16.5M 0.13% 133
2025
Q1 		$141M Sell
290,074
-166,513
-36% -$77.6M 0.19% 105
2024
Q4 		$184M Sell
456,587
-121,926
-21% -$56.5M 0.23% 92
2024
Q3 		$269M Sell
578,513
-87,699
-13% -$42.1M 0.34% 66
2024
Q2 		$312M Buy
+666,212
New +$289M 0.42% 49
2024
Q1 		– Sell
-664,034
Closed -$270M – 711
2023
Q4 		$270M Sell
664,034
-9,223
-1% -$3.41M 0.44% 48
2023
Q3 		$234M Buy
673,257
+57,839
+9% +$20.2M 0.41% 50
2023
Q2 		$217M Sell
615,418
-15,682
-2% -$5.28M 0.37% 54
2023
Q1 		$199M Sell
631,100
-6,346
-1% -$1.9M 0.39% 55
2022
Q4 		$184M Buy
637,446
+4,932
+0.8% +$1.5M 0.4% 54
2022
Q3 		$183M Sell
632,514
-49,384
-7% -$14.2M 0.43% 50
2022
Q2 		$192M Sell
681,898
-6,790
-1% -$1.82M 0.43% 53
2022
Q1 		$180M Buy
688,688
+24,532
+4% +$5.82M 0.33% 65
2021
Q4 		$148M Buy
664,156
+8,960
+1% +$1.74M 0.25% 86
2021
Q3 		$119M Buy
655,196
+43,410
+7% +$8.48M 0.22% 98
2021
Q2 		$123M Buy
611,786
+52,853
+9% +$11.1M 0.23% 100
2021
Q1 		$120M Buy
558,933
+121,997
+28% +$26.8M 0.25% 93
2020
Q4 		$102M Buy
+436,936
New +$100M 0.3% 102

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Swedbank's VRTX Position: Q2 2026 in Review

Swedbank increased its Vertex Pharmaceuticals (VRTX) stake by 4% in Q2 2026, buying an estimated $4.83M and bringing the position to 282,444 shares worth $140M. The position accounts for 0.12% of the portfolio, ranked #135.

Swedbank first reported a position in VRTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $312M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Swedbank held 282,444 shares of Vertex Pharmaceuticals worth $140M as of Q2 2026.
  • Swedbank bought 10,891 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.83M.
  • Vertex Pharmaceuticals made up 0.12% of Swedbank's portfolio in Q2 2026, its #135 holding.
  • Swedbank first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Swedbank's Vertex Pharmaceuticals position peaked at $312M in Q2 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Swedbank's 13F filing for Q2 2026, filed 15 Jul 2026.